New guidance urges improved reporting of important outcomes for patients in trials publications

Clinical trials provide us with the best evidence to guide patient treatment and inform health policy. Yet, crucial information, on outcomes reported directly by patients such as their quality of life, is often left out of clinical trial publications, according to international researchers.

Patient Reported Outcomes (PROs) include assessments of quality of life, symptoms and satisfaction with care. They can provide important information about the patients' perceptions and experiences of their disease and treatment. This information can be used to inform patient centered care.

Clinical trial publications often do not report these outcomes, or incompletely report or omit important information. As a result clinicians are unlikely to use the information in practice and in shared decision-making with patients.

"The assessment of PROs in takes valuable patient time and is costly. Poor quality reporting may limit the use of PRO data to inform patient care. This may be viewed as unethical and wasteful of limited resources." says Dr Melanie Calvert of the University of Birmingham, first author of the study published online today (February 27) in the which provides new guidance aimed at promoting improved reporting of PROs in clinical trials.

Evidence-based recommendations to improve the completeness of reporting of from the CONSORT (Consolidated Standards of Reporting Trials) group are widely endorsed by and have led to improvements in trial reporting over time. However, the existing guidance did not include key items relevant to optimal PRO reporting.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Cambodia bans 'virgin surgery' adverts

5 hours ago

The Cambodian government has ordered a hospital to stop advertising so-called virginity restoration procedures, saying it harms the "morality" of society.

What's happening with your donated specimen?

20 hours ago

When donating blood, plasma, human tissue or any other bodily sample for medical research, most people might not think about how it's being used. But if you were told, would you care?

Amgen tops Street 4Q forecasts

Jan 27, 2015

Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.